Age Gene/Environment Susceptibility Reykjavik Study

NCT ID: NCT03269656

Last Updated: 2017-09-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

5764 participants

Study Classification

OBSERVATIONAL

Study Start Date

2002-01-01

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

5764 men and women in Iceland, aged 66 to 96 years entered the Ages Gene/Environment Susceptibility (AGES) - Reykjavik Study. Serum 25(OH)D was measured in 5,519 of all 5,764 (96%) participants at study entry in year 2002 through 2006. The main emphasis was on exploring whether pre-diagnostic serum levels of 25(OH)D were associated with survival after cancer diagnosis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AGES-Reykjavik participants

Exploring whether pre-diagnostic serum levels of 25(OH)D among older individuals living in Iceland were associated with survival after cancer diagnosis. We also assessed the risk of being diagnosed with cancer in association with 25(OH)D levels.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* To participate in the AGES-Reykjavik study

Exclusion Criteria

* To be diagnosed with cancer before study entry
Minimum Eligible Age

66 Years

Maximum Eligible Age

98 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Iceland

OTHER

Sponsor Role collaborator

Icelandic Heart Association

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Johanna Torfadottir, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Iceland

References

Explore related publications, articles, or registry entries linked to this study.

Harris TB, Launer LJ, Eiriksdottir G, Kjartansson O, Jonsson PV, Sigurdsson G, Thorgeirsson G, Aspelund T, Garcia ME, Cotch MF, Hoffman HJ, Gudnason V. Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics. Am J Epidemiol. 2007 May 1;165(9):1076-87. doi: 10.1093/aje/kwk115. Epub 2007 Mar 10.

Reference Type BACKGROUND
PMID: 17351290 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2723948/

Age, Gene/Environment Susceptibility-Reykjavik Study: Multidisciplinary Applied Phenomics

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NO1-AG-1-2100

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

ZIAEY000401

Identifier Type: NIH

Identifier Source: secondary_id

View Link

IHA

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Finnish Vitamin D Trial (FIND)
NCT01463813 COMPLETED NA
Vitamin D for Chemoprevention
NCT00585637 COMPLETED PHASE1
Improving Functionality in Older People
NCT03611049 TERMINATED PHASE2